RAS-mediated tumor stress adaptation and the targeting opportunities it presents

• Main Authors: Alexandra Redding (Author), Andrew E. Aplin (Author), Elda Grabocka (Author)
• Format: Book
• Published: The Company of Biologists, 2022-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1754-8403; 1754-8411; 10.1242/dmm.049280
• Keywords: ras; tumor-associated stress; ras-pathway targeting; drug resistance; stress adaptation; Medicine; R; Pathology; RB1-214
• Source: Disease Models & Mechanisms, Vol 15, Iss 2 (2022)

Cellular stress is known to function in synergistic cooperation with oncogenic mutations during tumorigenesis to drive cancer progression. Oncogenic RAS is a strong inducer of a variety of pro-tumorigenic cellular stresses, and also enhances the ability of cells to tolerate these stresses through multiple mechanisms. Many of these oncogenic, RAS-driven, stress-adaptive mechanisms have also been implicated in tolerance and resistance to chemotherapy and to therapies that target the RAS pathway. Understanding how oncogenic RAS shapes cellular stress adaptation and how this functions in drug resistance is of vital importance for identifying new therapeutic targets and therapeutic combinations to treat RAS-driven cancers.